Mark Emberton

Mark’s ground-breaking work in prostate cancer research and treatment has earned him an international reputation in academic and medical circles.

Mark applies his expertise in three influential roles: leading the Faculty of Medical Sciences at University College London (UCL) as its Dean, treating patients at University College London Hospital (UCLH) and researching prostate cancer. He is also a founding pioneer of the charity Prostate Cancer UK.

Prostate cancer research with impact

Mark is one of the world’s leading prostate cancer researchers. His research has been published in more than 300 peer-reviewed scientific papers in journals including BMJ, Lancet Oncology and European Urology.

His work to evaluate the effectiveness of self-management for chronic male lower urinary tract symptoms, led to the development of a self-management intervention programme that saves the NHS around £20 million annually.

Mark also oversaw the UCL trial of multiparametric MRI (mpMRI) as a first line investigation for men suspected of having clinically localised prostate cancer. In 2019 this work won UK Research Paper of the Year at the BMJ Awards, and was approved as a first-line approach in formal guidance published by the National Institute for Health and Care Excellence (NICE),

Mark has also won a Pioneer Award for development of applications for the treatment of prostate cancer, and a Golden Telescope BAUS Award 2007, for outstanding urologist within ten years of appointment.

Education Leadership

As its Dean, Mark leads the UCL Faculty of Medical Sciences, which is number 1 in London for Medicine and number 9 in the world. He also holds the post of Professor of Interventional Oncology, Division of Surgery and Interventional Science at UCL.

As a Visiting Professor, Mark has collaborated with The Mayo Clinic at UCLA, Jikkei University in Tokyo, and Cornell University in New York. He was recently awarded the prestigious title of Honorary Skou Professor in the Department of Clinical Medicine at Aarhus University, Denmark. Mark gives approximately 20 invited lectures per year in the UK and abroad.

Amongst other titles, Mark is also Clinical Director of the Clinical Effectiveness Unit in the Royal College of Surgeons of England, Chair of the Clinical Guidelines Committee and a founding partner of London Urology Associates.



« Back